Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.15 USD
-1.71%
Market Closed
Updated:
May 15, 2024
Adaptimmune Therapeutics PLC
Research & Development
|
Adaptimmune Therapeutics PLC
Research & Development Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Research & Development
-$126.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$124.4m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Research & Development
-$122.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$159.2m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Research & Development
-£163.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Adaptimmune Therapeutics PLC's Research & Development?
Research & Development
-126.5m
USD
-126.5m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Research & Development amounts to -126.5m USD.
What is Adaptimmune Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
-5%
Over the last year, the Research & Development growth was 1%. The average annual Research & Development growth rates for Adaptimmune Therapeutics PLC have been -11% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
